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Background: In the United Sates (US), more than 400,000 people have end stage renal 
disease (ESRD) or chronic kidney disease (CKD) stage 5D requiring in-center 
hemodialysis (HD), and approximately $35 billion is spent annually in healthcare costs. 
Maintenance HD patients with ESRD have increased protein (1.2 g/kg/d) and energy (30-
35 kcal/kg/d) requirements, but the average protein and energy intake in these patients is 
only 0.8-1.0 g/kg/d and 20-25 kcal/kg/d, respectively. Subsequently, protein-energy 
wasting (PEW) is common, affecting up to an estimated 75% of maintenance HD 
patients, and low protein and energy intake are one of the main contributors of PEW. 
Consequences of PEW range from diminished quality of life (QoL) to increased mortality 
rate, and high protein meals during HD may help prevent PEW. However, eating during 
HD is often discouraged in US dialysis centers due to possible adverse events, 
particularly postprandial hypotension. The aim of this pilot study was to determine the 
effects of high protein meals during HD on symptomatic intradialytic hypotension (SH).
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Methods: 19 HD patients were recruited from 2 shifts (~10AM-2PM, MWF & TTS) at 
one dialysis center for a 9-week, non-randomized, parallel arm study. Patients in the 
intervention group (N = 10) received meals with 30 grams of protein and one-third of 
sodium, potassium, phosphorus, and fluid recommendations according to Kidney Disease 
Outcomes Quality Initiative (KDOQI) for 25 dialysis sessions. Patients in the control 
group (N = 9) received a control social interaction. Blood pressure data from 2 months 
prior to the initiation of study and during the study (25 sessions each) were collected. 
Secondary outcomes included serum/plasma biochemistries (monthly renal laboratories 
to assess nutritional status and electrolyte balance), dialysis compliance, fluid retention, 
sleep, and other QoL measures. The difference in the frequency of SH events within 
groups for 2-month pre-study and during study, was determined by Wilcoxon signed-rank 
test, and between group differences were determined by Wilcoxon rank-sum test. Other 
outcomes were assessed using repeated measures ANOVA with fixed effects for group, 
time, and group × time interaction, and random effect for subject nested within group.   
Results: One patient in the intervention arm withdrew from the study upon 
discontinuation of dialysis. Thus, N = 9 patients per group completed the study and are 
included in the analyses. Patients were 62 ± 16 years old, 55% female, and had been on 
dialysis for 3.4 ± 2.6 years. In the intervention group, there were 4 SH events in 3 
patients over 25 dialysis sessions in the pre-study period and 12 SH events in 4 patients 
over 25 dialysis sessions during the study period. In the control group, there was 1 SH 
event in 1 patient pre-study and 5 SH in 4 patients during study. Change in the frequency 
of SH events from pre-study to during study was not different between groups (P = NS). 
The average lowest mean arterial pressure (MAP) was significantly higher in the control 
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group compared with the intervention group, but difference between pre-study and during 
study was not significant for either group. Serum albumin and pre-albumin did not 
change throughout the study and when compared with values obtained during the pre-
study period in either group. There were no significant improvements in QoL with the 
meal intervention, but results showed that HD patients had poorer quality of life and 
sleep quality compared with the general US population. When patients were asked “how 
interested would you be in receiving nutritious meals during dialysis?” at the end of 
study, 70% of patients responded ≥ 4 (5-point scale, 5 = very interested; P = NS between 
groups). 
Conclusions: These pilot data suggest that meals during HD do not increase the 
frequency of SH events. Additionally, patients generally have positive attitudes towards 
receiving meals. However, changes in nutritional status indicators, electrolyte balance, 
and QoL were not observed in either group. Larger, longer-term studies are needed to 




CHAPTER 1. INTRODUCTION 
1.1 Introduction 
1.1.1 Prevalence and Incidence of End Stage Renal Disease 
According to United States Renal Data System (USRDS), end stage renal disease 
(ESRD) is defined by complete and irreversible kidney failure [91]. ESRD also refers to 
the last stage of chronic kidney disease (CKD), or CKD stage 5, which indicates that less 
than 15% of kidney function is remaining. ESRD is a major public health concern in the 
United States (US) with a high prevalence and incidence [91]. As of December 31st, 
2011, more than 615,000 individuals in the US were enrolled in the ESRD Medicare-
funded program with total annual healthcare treatment costs of approximately $35 billion 
[39, 40]. Additionally, the prevalence of ESRD is increasing. The prevalence has 
increased by 29% as well as the number of patients receiving dialysis as treatment since 
2000. The number of prevalent cases reached 701,353 at the end of 2015, compared to 
only 661,648 at the end of 2013 in the US [91].  
Since 2000, the incidence of ESRD also has increased as there were 117,162 new 
cases of ESRD reported at the end of 2013 [91]. Additionally, millions of non-ESRD 
patients are at an increased risk of ESRD including African Americans, those who are 
diagnosed with diabetes and/or hypertension, and those who have a family history of 
CKD and/or ESRD. Diabetes is known as the most common primary cause of ESRD, 
accounting for approximately 44% of new cases [17, 91].
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1.1.2 Treatment for End Stage Renal Disease 
There are two main methods of treatment available for ESRD patients: dialysis 
and kidney transplant. Patients are advised to consult their nephrologist to determine the 
best treatment for them [22]. Kidney transplant has advantages, which include greater 
freedom, higher vitality, and a less strict diet [22]. However, the side effects of kidney 
transplant, especially transplant rejection and infection, are common after the procedure. 
Therefore, immunosuppresants are necessary, along with following a healthy lifestyle 
[22]. Due to long transplant waitlists, risk of rejection, and other factors that disqualify 
patients as good transplant candidates, most ESRD patients need to undergo kidney 
dialysis treatment.  
There are two types of dialysis, which include hemodialysis (HD) and peritoneal 
dialysis. These options are available for patients with less than 15% of kidney function 
remaining. Prior to the initiation of dialysis, patients are required to undergo a surgical 
procedure to place a catheter into their abdomen for peritoneal dialysis or, for HD, 
placement of an arteriovenous fistula or graft. In peritoneal dialysis, the peritoneal cavity 
is filled with dialysate to remove extra fluid and waste products such as nitrogen and 
creatinine [23]. Meanwhile, HD requires the use of a dialysis machine, which removes 
waste products and excess fluid, helps to balance electrolytes, and controls blood pressure 
(BP) by working as an “artificial kidney” [23]. 
HD can be done either at home or in-center and there are advantages and 
disadvantages for both. At the end of 2009, 398,861 ESRD patients were being treated 
with some form of dialysis and approximately 10 times as many ESRD patients received 
in-center HD as those received peritoneal dialysis and home HD combined [18]. ESRD 
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patients are considered as maintenance hemodialysis (MHD) patients as they are being 
treated for chronic or permanent kidney failure. For home HD, three options are available 
for patients, which include conventional home HD, short daily home HD, and nocturnal 
home HD. Similar to in-center HD, conventional home HD is done three times a week 
and each session takes three to four hours depending on patients. Short daily home HD is 
done five to seven times a week but the duration of treatment is shorter than the 
conventional home HD, about 2 hours. Nocturnal home HD provides longer and slower 
treatments as patients sleep and can be done every other night [24]. Short daily and 
nocturnal home HD can be combined and patients typically report having positive 
experiences as well as better subjective outcomes such as less fatigue and better sleep 
quality. Home HD also allows for more flexible treatment schedule while in-center HD 
patients are recommended to visit their dialysis center typically three times a week for 
dialysis sessions that average four hours in duration. However, a few weeks to several 
months of training are required prior to the initiation of home HD for safety and price can 
become an issue [24]. Therefore, home HD is not suitable for everyone despite its 
convenience. On the other hand, finding dialysis centers can be challenging for in-center 
HD patients as the growing number of HD patients may be insufficient to accommodate 
every affected individual [91].  
ESRD patients on HD are typically prescribed a renal diet regimen to maximize 
the effectiveness of treatments, but this presents with it various nutritional challenges, 
which will be discussed further in the next section. 
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1.1.3 Nutrition Recommendations and Challenges in Hemodialysis Patients 
HD patients have nutrient recommendations that vary from the general 
population. Meeting these nutritional recommendations from the Kidney Disease 
Outcomes Quality Initiative (KDOQI) guidelines is considered an important part of 
disease management for HD patients. Particularly, HD patients have increased energy 
and protein requirements as the treatment process can further induce a catabolic effect in 
addition to the catabolic effect of the disease itself [93]. Yet, meeting recommended 
energy and protein intakes can be challenging for many HD patients due to co-existing 
physical-, social-, and psychological-related problems. This section will explain in detail 
the nutrient recommendations set by KDOQI and the challenges that hinder HD patients 
from following recommendations. 
	
1.1.3.1 Protein and Energy Recommendations 
Protein and energy recommendations for ESRD patients undergoing HD 
treatment are higher than for the general population. Based on KDOQI guidelines, 
patients on HD require 1.2g/kg dry body weight of protein and 30-35kcal/kg dry body 
weight per day to maintain proper protein balance and nutritional status [22]. 
Additionally, it is recommended that more than 50% of protein consumed is from high 
biological value protein sources, such as meat, dairy, or eggs, which include all 9 
essential amino acids that are required by humans [22].  However, the average protein 
and energy intake of HD patients are estimated to be at 0.8-1.0g/kg and 20-25kcal/kg per 
day, leaving dialysis patients vulnerable to the consequence of protein-energy wasting 
(PEW), which typically is evidenced by low serum albumin level (discussed further in 
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section 1.1.4.1) [36, 83]. In order to prevent the severe nutritional deficiencies and/or 
meet protein and energy recommendations by KDOQI guidelines, studies suggest that 
providing oral nutritional supplements and/or high-protein meals during dialysis may be 
beneficial for HD patients (discussed in section 1.3), and this approach has been 
advocated by some in the nephrology field [35].   
	
1.1.3.2 Other Nutrient Requirements and Fluid Restrictions 
One issue that presents a major challenge for HD patients to meet their high 
protein and energy requirements is that HD patients have other concurrent nutrient and 
fluid restrictions (Table 1.1). HD patients are usually required to limit sodium, potassium, 
and phosphorus intake to reduce the risk of co-morbidities such as cardiovascular disease 
(CVD) and bone disease [29]. According to KDOQI guidelines, HD patients are 
recommended to restrict their sodium intake to 2000-3000 mg per day, potassium intake 
to 2000-3000 mg per day, and phosphorus intake to 800-1000 mg per day [22]. The fluid 
recommendation by KDOQI guidelines is based on fluid output plus 1000 Ml per day 
[22]. These fluid and mineral restrictions are imperative to maintain the effectiveness of 
dialysis treatment and if well managed, they may attenuate the risk of CVD and bone 
disease [40]. However, it is difficult to adhere to such recommendations due to various 






Table 1.1. Nutrient Recommendations for HD Patients versus General Population 
Nutrient Recommendation for HD Patients Recommended for 
General Population 
Protein 1.2 g/kg/d 0.8 g/kg/d 
Energy 35 kcal/kg/d 20-25 kcal/kg/day 
Sodium  2000-3000 mg/d 2300 mg/d 
Potassium  2000-3000 mg/d 4700 mg/d 
Phosphorus  800-1000 mg/d; or 1 mg/g protein 700 mg/d 
Fluid  Fluid output + 1000 Ml/d 3000 Ml/d 
	
1.1.3.3 Challenges in Meeting Nutritional Needs in Hemodialysis Patients 
According to Burrows et al., HD patients do not meet their nutrient needs set by 
KDOQI guidelines due to co-existing physical, social, and psychological problems 
especially on dialysis treatment days [6]. Commonly reported problems such as 
nausea/vomiting, loss of appetite, altered taste sensation, and poor quality of life (QoL) 
are associated with decreased food intake in HD patients [53]. Other factors induced by 
the HD treatment such as post-dialysis fatigue (PDF) are also associated with reduced 
energy and protein intake [38]. Also, fast food consumption is highly prevalent in this 
population due to its convenience, affordability, and palatability, which is thought to be 
consequent to patients’ fatigue and decreased ability or willingness to prepare food at 
home [7]. This fact is worrisome as it may affect HD patients’ co-existing conditions 
such as obesity, CVD, and malnutrition along with excess consumption of sodium and  
phosphorus from fast food. Butt et al. [7] conducted a cross-sectional study where they 
obtained data on fast food consumption, nutrient intake, and biochemical parameters in 
HD patients over a 4-month period. One-hundred ninety-four participants with a serum 
albumin level lower than 3.7g/Dl in 44 dialysis centers located in northeast Ohio were 
studied. Of these patients, 42% (N = 81) consumed at least one fast food meal or snack 
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over the 4 days. In younger, Caucasian HD patients, fast food consumption was more 
frequent, which was found to be associated with longer duration of HD treatment. As fast 
food consumption increased, subjects consumed more kilocalories, carbohydrate, total 
fat, saturated fat, and sodium compared to subjects who limited their fast food 
consumption. Additionally, kilocalories consumed were largely from carbohydrate and 
fat intake. Protein intake, however, was not different in subjects who consumed an 
average of 0.25 fast food meals a day from those who completely avoided fast food 
consumption. HD patients with frequent fast food consumption, or an average of 0.75 or 
more fast food meals per day, was found to be linked to higher serum phosphorus and 
interdialytic weight gain (IDWG) than HD patients who completely avoided fast food 
consumption [7]. As this specific intake pattern was found to be associated with higher 
serum phosphorus levels, it may further disturb the disordered mineral regulation such as 
hyperphosphatemia and increase the risk of CVD and bone disease in HD patients [65]. 
Overall, the authors suggested that limiting fast food consumption along with dietary 
restriction of phosphorus would be beneficial for CKD patients [7]. 
Due to difficulties with complying to nutrient recommendations and restrictions, 
inadequate caloric and protein intake and poor nutritional status are common in HD 
patients [6]. Those negative patterns in lifestyle may lead to negative nutrition-related 
consequences, increasing the risk of adverse health outcomes in HD patients. In next 
section, the effects of poor nutritional status commonly found and/or reported in HD 




1.1.4 Nutritional Consequences in Hemodialysis Patients 
Patients undergoing HD have an annual mortality rate of 20% which is associated 
with their higher rates of catabolism and heavily influenced by factors such as 
uncontrolled PEW, post-dialysis fatigue (PDF), and reduced QoL [21].   
	
1.1.4.1 Protein-Energy Wasting 
 According to International Society of Renal Nutrition and Metabolism, “PEW is 
the multiple nutritional and catabolic alterations that occur in CKD and associated with 
morbidity and mortality” [12]. Criteria are available for the clinical diagnosis of PEW 
and CKD. Patients with PEW meet three or more of these criteria to be diagnosed with 
CKD-related PEW: serum albumin lower than 3.8 g/Dl, serum pre-albumin lower than 30 
mg/Dl, serum cholesterol less than 100 mg/Dl, body mass index (BMI) lower than 23 
kg/m2, unintended weight loss 5% or greater over three months, less than 10% of total 
body fat, loss of muscle mass greater than or equal to 5% over three months, and 
unintended low dietary protein and energy intake [79]. PEW, therefore, corresponds to 
the malnutrition diagnosis of “malnutrition of chronic disease” according to the American 
Society for Parenteral and Enteral Nutrition & Academy of Nutrition and Dietetics 
guidelines [103]. The prevalence of PEW is high – it is estimated that up to 75% of MHD 
patients suffer from PEW, with consequences of that range from diminished QoL to 
increase mortality [25]. 
PEW is known as the strongest risk factor for adverse outcomes and death in HD 
patients [52]. In fact, Kalantar-Zadeh et al. found that the mortality of HD patients may 
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be affected by short-term consequences of PEW; therefore, interventions that may 
improve their nutritional status and prevent further wasting may reduce mortality [34].  
One of the major consequences of PEW is unintended weight loss, which may 
worsen especially on dialysis treatment days due to catabolic processes induced by the 
treatment and disease itself [11]. When evaluating weight loss or gain in HD patients, it is 
critical to use “dry” weight, or post-dialysis weight, as patients can retain up to several 
kilograms of fluid between dialysis treatments. Kalantar-Zadeh et al. suggested that 
unintended weight loss may be induced by low protein and energy intakes of dialysis 
patients compared to their recommended dietary requirement [36]. Also, if HD patients 
fail to comply with the KDOQI recommendations on nutrient intakes, they are likely to 
lose between 1 to 3 kg of lean mass per year [73]. Thus, unintentional weight loss is 
another significant problem among HD patients. A retrospective cohort study by 
Campbell et al. [11] examined the validity of the screening criteria for malnutrition risk 
in HD patients (N = 217). They found that HD patients who experienced a clinically 
significant weight loss (more than 5% of their body weight within 6 months) had a 3-fold 
greater risk of death. Additionally, patients with significant weight loss had an increase in 
hospital stay and costs, but such effect was attenuated when adjusted for comorbidities, 
age, and years on dialysis [11]. Therefore, Campbell et al. [10, 11] suggested the 
establishment of the consistent nutrition screening as a feasible method to avoid the effect 
of PEW, especially unintended weight loss in particular. 
Even though about one-third of HD patients are obese, PEW is a greater concern 
in this population [54, 61]. This has been described as the ‘obesity paradox’, where 
patients with higher BMI at the initiation of dialysis are less vulnerable to the negative 
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consequences of PEW, and have improved survival rate [8]. Regardless of patient’s 
starting BMI, however, studies have shown that improving protein intake may be 
beneficial in avoiding or mitigating the consequences of PEW [9, 73, 90]. Gaining greater 
than 1% initial body weight within 6 months is indicative of attenuated effects of PEW. 
Such weight gain is also associated with better survival rate in HD patients who fall in 
underweight (< 20 kg/m2), normal weight (20-24 kg/m2), and overweight (25-29 kg/m2) 
categories of BMI regardless of their age, sex, diabetes, and the severity of obesity, which 
could be partly achieved by proper nutrition intervention [8, 70]. Conversely, 
uncontrolled PEW may result in an imbalance between available nutritional stores and 
metabolic demands, which contribute to acute rise in inflammation and further increase 
wasting [74]. To develop better control over the progression of PEW, some studies 
suggest the use of supplemental nutrition as well as providing a proper renal-specific diet 
before, during, or after dialysis regardless of their BMI [36, 57, 83].  Evidence suggests 
that the provision of supplemental nutrition and/or renal-specific diet may improve net 
protein balance, promote skeletal muscle protein synthesis, and reduce overall catabolism 
in HD patients [9, 73, 90]. However, conflicting findings question about the effectiveness 
and feasibility of such practice in terms of safety, price, and convenience, which will be 
discussed in section 1.3. 
	
1.1.4.2 Post-Dialysis Fatigue 
PDF is the feeling and expression of tiredness or low vitality observed typically 
after dialysis, which is another complication commonly reported by HD patients [86]. 
Even though as many as 97% of dialysis patients are affected by fatigue, it often goes 
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unrecognized due to its subjectivity [33]. Many modifiable and non-modifiable factors 
including but not limited to anemia, malnutrition, and inflammation contribute to PDF, 
which is associated with higher mortality in HD patients; therefore, some studies have 
focused on identifying possible predictors of PDF in HD patients [38, 58]. 
Jhamb et al. [32] conducted the Hemodialysis (HEMO) study, which was a 
randomized controlled trial of 1,846 MHD patients, to examine the correlates and 
outcomes of fatigue in this population. The Short Form-36 Health Survey (SF-36), a 
validated questionnaire [32], was used to measure fatigue. Importantly, results showed 
that a 1 g/Dl increase in albumin was associated with an increase in vitality score by 7.7 
points and 21% decrease in risk of death in this population, supporting the relationship 
between serum albumin, PDF, and mortality in HD patients. Other than serum albumin, 
other independent predictors of fatigue in HD patients were: severe comorbid conditions, 
diabetes, poor QoL, and the use of sleep medications. In terms of outcomes, patients with 
worsening fatigue or vitality score lower than 50, had increased risk of death from CVD 
events as shown by adjusted hazard ratio of 1.14. In this study, more than 50% of patients 
studied had a vitality score similar to individuals with severe depression, patients with 
lupus, and cancer patients undergoing chemotherapy. Jhamb et al., therefore, emphasized 
the importance of appropriate nutrition, pharmacological, and exercise-based 
interventions to attenuate the effects of fatigue in this population [32].  
Health-related quality of life (HRQOL) is another effective way to measure the 
severity of PDF in HD patients as it has been extensively evaluated in ESRD populations 
[100]. Jhamb et al. [31] conducted a longitudinal cohort study that examined the 
correlates and outcomes of PDF in HD and peritoneal dialysis patients. They utilized the 
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CHOICE Health Experience Questionnaire (CHEQ), which includes questions from the 
SF-36 to determine the overall HRQOL of participating patients. A higher score on the 
CHEQ indicated more vitality and less fatigue in HD patients. Other information such as 
biochemical variables and medical information were collected as covariates of PDF. Low 
vitality was strongly associated with lower physical functioning, mental health, bodily 
pain, and sleep quality scores on SF-36. Furthermore, higher C-reactive protein (CRP) 
and interleukin-6 (IL-6), which are markers of inflammation, were associated with 
decline in vitality in HD patients [31]. This finding, however, was expected, as higher 
levels of CRP are linked to chronic inflammatory states induced by CKD which may 
exacerbate inflammation, lower functional status, and elevate energy needs as well as the 
mortality rate in HD patients [5]. In terms of other inflammatory markers such as 
interleukin-1 and tumor necrosis factor-α, evidence was limited to propose their possible 
association with PDF. Additionally, a decline in vitality over one year resulted in a 
median survival of three years compared with 3.8 years for those with stable or improved 
vitality suggesting the strong association between vitality and HD patient survival. 
Therefore, Jhamb et al. suggested the implementation of periodic examination of HD 
patients’ QoL and vitality level may be a feasible method to maximize the effect of 
dialysis treatment both physically and mentally [31]. 
Along with increasing mortality, PDF plays an influential role in HD patients’ 
perspectives and adherence to dialysis treatment as evidenced by several studies. A study 
by Sklar et al. indicated that HD patients need more than five hours of sleep to recover 
from PDF, which suggests its possible effect on patient adherence to dialysis [86]. 
Similarly, Ramkumar et al. found in a cross-sectional survey that 94% of in-center HD 
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patients are willing to accept more frequent HD if it increases their energy and vitality 
[76]. If PDF is not managed properly, low adherence to dialysis may increase IDWG as 
well as mortality especially if a strict dietary restriction is not followed by HD patients 
[76].  
Even though demographic and clinical factors are found to be heavily associated 
with PDF, it is still difficult to predict and manage PDF due to its subjectivity [32, 85, 
86]. The development of feasible medical and nutrition interventions, therefore, is crucial 
considering the effect of PDF on mortality in HD patients [85]. 
	
1.1.4.3 Quality of Life 
The QoL of ESRD patients is affected by their mental health, physical health, and 
nutritional status [58]. Malnutrition is one of many risk factors of poor QoL, and the 
prevalence of malnutrition is as high as 40-70% in ESRD patients [38, 39, 58]. Co-
existing depression, anxiety, stress, and/or poor sleep habits also are known to be 
independent predictors of poor QoL in ESRD patients [72, 102]. Among these factors, 
depression and poor sleep quality are most prevalent in HD patients [42, 45]. About 43% 
of HD patients are depressed and/or show related symptoms, and as high as 80% of HD 
patients have sleep apnea [27, 101]. The impact of depression on HD patients is 
especially significant as Lopes et al. found that depressed HD patients have 42% higher 
mortality [60]. However, these factors are not assessed frequently in clinical settings 
despite its significant influence on QoL and prevalence [97].  
Depression is often underdiagnosed and undertreated in HD patients [60]. 
Depression in HD patients is associated with myriad contributing factors, both nutrition 
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and non-nutritional in nature. These include poor oral intake, poor sleep quality, and 
inflammation. Studies have also shown that depression is associated with a number of 
negative consequences in HD patients [42, 48, 58]. Depression is associated with poor 
oral intake which could worsen malnutrition or PEW in ESRD patients [4]. A study by 
Koo et al. suggested that using antidepressant medication may be helpful for HD patients 
as it was shown to reduce depressive symptoms and improve food intake [49]. On the 
other hand, depression is found to have a positive relationship with pro-inflammatory 
cytokines, which could accelerate protein catabolism in ESRD patients based on findings 
by Stenvinkel et al. [88]. According to Leonard and Whirledge, the extended elevation of 
glucocorticoid concentration, which is a reaction to malnutrition and stress, causes a de-
sensitization of the central glucocorticoid receptors and possibly receptors on 
macrophages especially in major depression [59, 98]. Such changes may lead to increased 
release of pro-inflammatory cytokines from activated macrophages in the periphery and 
brain along with elevated release of acute phase protein from the liver. Therefore, 
upregulated pro-inflammatory cytokines such as CRP and IL-6 from depression may 
induce inflammation-induced malnutrition and increase mortality rate in HD patients. 
This is in addition to other factors such as hypercatabolism from dialysis treatment that 
stimulate the production of inflammatory cytokines [59].  
Sleep disorder is another significant and prevalent factor involved in the decline 
of QoL in ESRD patients. Causes of sleep disorder are similar to depression and its 
severity is influenced by physical, social, and psychological factors in HD patients. 
ESRD patients frequently complain of delayed sleep onset, frequent awakening, 
restlessness, and daytime sleepiness [27]. Studies found that poor nocturnal sleep and 
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increased daytime sleepiness are associated with poorer QoL and sleep-disordered 
breathing is associated with increased risk of CVD, morbidity, and mortality in HD 
patients [72]. Overall, quality of sleep is another reliable factor that can predict QoL in 
HD patients [29].  
Bilgic et al. conducted a cross-sectional study to examine the association between 
nutritional status, the presence of depression, sleep disorder, and QoL [4]. The 
Malnutrition-Inflammation Score (MIS), BDI questionnaire, and Pittsburgh Sleep Quality 
Index (PSQI), and SF-36 were utilized to measure HD patients’ nutritional status, 
symptoms of depression, sleep quality, and QoL respectively. The data showed that 
63.8% of patients were depressed and 48.9% of those had moderate-to-severe depression. 
Lower serum albumin, higher CRP, higher MIS scores, poorer sleep quality, and lower 
SF-36 scores were found in patients with moderate-to-severe depression, and that poor 
nutritional status was significantly associated with depression, sleep disorders, and lower 
QoL. Bilgic et al. suggested that these factors could eventually affect morbidity and 
mortality of HD patients if not managed properly. In conclusion, devitalizing factors are 
shown to be closely related to each other, establishing once again that PEW is a crucial 
factor that influences clinical outcomes and mortality in HD patients [4]. In next section, 
ways to detect PEW and malnutrition in HD patients will be discussed. 
 
1.1.5 Nutritional Status Indicators 
Nutritional status indicators commonly used to evaluate nutritional status of HD 
patients are albumin and, to a lesser extent, pre-albumin [22]. Albumin is a water-soluble 
protein synthesized in the liver. Its rate of synthesis varies in response to nutritional status 
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and stress, indicating that serum albumin level is not specific to an individual’s protein 
status. It is a negative acute phase reactant, thus, its level decreases in the presence of 
inflammation. Additionally, due to its half-life of 3 weeks, it is difficult to identify 
individual’s current protein intake [44]. Despite these limitations, albumin is still used as 
a key nutritional marker that is widely used as a quality index in dialysis centers and to 
diagnose malnutrition in CKD patients. According to KDOQI guidelines, maintaining a 
value of 4.0 g/Dl or greater serum albumin is highly recommended for ESRD patients; 
yet, the optimal level of serum albumin for the ESRD population has not been determined 
[22, 37] 
 Pre-albumin, also referred to as transthyretin, is another nutritional status 
indicator that is also synthesized in the liver. Despite its name, it is not related to the 
protein albumin. According to KDOQI guidelines, it is a valid and clinical useful 
measure of protein-energy nutritional status in MHD patients [22, 75]. Like albumin, it is 
a negative acute phase reactant that is also sensitive to the presence of inflammation. 
However, compared to albumin, its shorter half-life of 2 days makes it a better indicator 
of current protein intake of individuals [51].  According to KDOQI guidelines, pre-
albumin greater than or equal to 30 mg/Dl is desirable for HD patients [22]. 
 
1.1.6 Nutrition during Dialysis as a Strategy for Improving Nutritional Status and Other 
Outcomes in Hemodialysis Patients 
Due to the high prevalence of poor nutrition in HD patients, studies have 
investigated ways to help them meet their nutritional needs and one of those is the 
provision of supplemental nutrition and/or meals during dialysis [47]. Studies show that 
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providing supplemental nutrition during HD in different forms (meals and liquid 
supplements) is effective in increasing skeletal muscle protein synthesis, reducing 
catabolism, and improving net protein balance in patients [9, 73, 90]. Despite its potential 
positive effect on nutritional status and QoL in HD patients as indicated by serum 
albumin, lean mass, and subjective global assessment in HD patients, potential negative 
outcomes like postprandial hypotension, choking, and gastrointestinal distress prevent 
dialysis centers from implementing such policy [46]. The next section will describe 
further the current practices in US dialysis centers and concerns over provision of 
nutrition during dialysis. 
 
1.2 Nutrition during Dialysis: Practices and Concerns 
Many industrialized countries including most European and Southeast Asian 
countries routinely allow food consumption and/or the use of supplemental nutrition 
during dialysis treatment, which is also used as an opportunity for providing nutrition 
education [36]. Additionally, evidence shows that HD patients in Germany, who 
routinely receive food or supplements during HD, have a higher survival rate compared 
to the US with a minimal number of adverse events [99]. Providing supplemental 
nutrition or meals during dialysis allows for consistent nutrient consumption that meets 
renal diet recommendations, which may help ease the consequences of poor nutrition 
status or dietary non-compliance in HD patients [35].  However, the provision of meals 
and/or oral nutritional supplements during dialysis raises certain concerns with 
nephrologists as well as other dialysis professionals, especially in the US, which are 
discussed below [46]. 
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1.2.1 Common U.S. and Worldwide Practices 
Dialysis centers in the US commonly restrict food consumption and/or the use of 
supplemental nutrition due to a variety of reasons. The first and most often cited reason is 
to prevent risk of postprandial hypotension in HD patients [21, 46]. Sherman et al. 
showed that patients are more susceptible to postprandial hypotension if food 
consumption were allowed during dialysis [81]. The association between meals or oral 
nutritional supplements provided during dialysis and the risk of postprandial hypotension 
will be elaborated in section 1.2.2. Second, the allowance of food consumption or the use 
of supplemental nutrition creates additional concerns over potential choking events, 
infections, spills, and pests, which may burden staff at the dialysis center [14, 21]. Lastly, 
the added expense of providing meals and/or supplemental nutrition is another concern 
that hinders the implementation of the nutritionally-optimal policy in the US [21].  
 Benner et al. conducted a study to determine current practices and beliefs 
regarding in-center food consumption during HD in the US [3]. In 2011, the first survey 
was conducted and then educational materials that promote eating during HD were sent 
to clinicians (registered dietitians, facility administrators, and medical directors). In 2014, 
a follow-up survey was conducted to evaluate any change in practices and beliefs in in-
center food consumption during HD after nutrition education. In 2011 and 2014, 1199 
and 1422 dialysis centers in the US completed the survey, respectively. In 2011, prior to 
receiving education materials promoting nutrition on dialysis, 28.6% of surveyed clinics 
did not allow eating during HD and 18.2% did not allow drinking during HD. Regarding 
clinician opinions on eating during HD, 23.1% of 1192 registered dietitians, 31.5% of 
1003 facility administrators, and 30.8% of 828 medical directors strongly discouraged 
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such policy in 2011. Based on responses collected in 2014, after receiving education 
material promoting nutrition on dialysis, the proportion of clinics not allowing eating 
during HD decreased significantly to 22.6%. Additionally, the percentage of clinicians 
strongly discouraging eating during HD also significantly decreased to 11.6% for 
registered dietitians (N = 1408), 25.2% for facility administrators (N = 1238), and 24.0% 
for medical directors (N = 978) [3]. Benner et al. suggested that as this study represents a 
significant portion of clinics in the US, it supports suggestions that the US has more 
restrictive policies regarding nutrition on dialysis compared with the rest of the world 
[46]. 
International practices in dialysis centers, however, differ from the US as 
evidenced by a study conducted by Kistler et al. [46]. Kistler et al. surveyed 73 clinicians 
at the 2014 International Society of Renal Nutrition and Metabolism conference in 
Wurzberg, Germany to describe international practices on eating during HD. Results 
showed that 85% of surveyed clinics allowed eating during HD while none of the 9 US 
clinics surveyed did. 64% of clinics surveyed provided oral nutritional supplements 
during HD. Despite high percentages in the allowance of eating during HD, clinicians 
still expressed concerns over possible adverse events, specifically hypotension, 
gastrointestinal issues, reduced treatment efficiency, spills or pests, choking, and 
infection control issues. However, those conditions were reported as rarely or never 
observed during treatments, 62.3%, 71.1%, 97.7%, 82.6%, 97.8%, and 95.6%, 
respectively. In conclusion, Kistler et al. suggested that such difference may contribute to 
the difference in patients’ serum albumin as well as mortality rates amongst countries, but 
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more studies are needed as there are conflicting findings regarding eating during HD and 
induction of hypotensive events in patients [46]. 
	
1.2.2 Postprandial Hypotension 
Hypotension is the major cited concern when food intake is allowed during 
dialysis [47]. There are two main causes of hypotension in the context of feeding during 
dialysis treatments. One is intradialytic hypotension (IDH), and the other is postprandial 
hypotension [46]. According to KDOQI, IDH is “a decrease in systolic blood pressure 
(SBP) by greater than or equal to 20 mm Hg or a decrease in mean arterial pressure 
(MAP) by 10 mm Hg associated with symptoms that include: abdominal discomfort, 
yawning, sighing, nausea, vomiting, muscle cramps, restlessness, dizziness or fainting, 
and anxiety” [22]. IDH is highly prevalent as it affects up to 40% of all HD treatments 
[15, 16] and it is caused by reduced baroreceptor sensitivity, significant amount of fluid 
removal, osmotic-induced intracellular water shifts, and acetate-induced vasodilation 
[85]. It can cause cardiac arrhythmias if not managed appropriately [22]. Furthermore, 
patients with autonomic dysfunction, a blunted response to hemodynamic stressors, 
reduced baroreflex function, and insulin resistance may have higher incidence of  
hypotension during dialysis treatment [82].   
Patients experiencing postprandial hypotension may show similar symptoms to 
IDH but excessive drops in BP happen after a meal [62]. HD patients, who are insulin 
resistant, aged, and/or with autonomic dysfunction, are more vulnerable to postprandial 
hypotension [30].  Evidence suggests that eating during HD can further increase the 
severity and frequency of hypotension in patients because food intake during HD may 
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decrease systematic vascular resistance, increase splanchnic sequestration of blood 
leading to decreased cardiac filling and cardiac output, or decrease splanchnic resistance 
leading to total peripheral resistance [20, 82]. A study conducted by Sherman et al. 
looked at the effect of eating during HD on 9 non-diabetic ESRD patients [81]. During 62 
out of 125 dialysis treatments (average 13 treatments/patient), meals that were composed 
of two slices of bread, two ounces of low sodium turkey breast, one teaspoon of regular 
mayonnaise, a slice of pound cake, and four ounces of cranberry juice cocktail were 
provided after one and a half or two hours after the initiation of dialysis. Additionally, 
two hours prior to dialysis, patients were asked to be fasted. In contrast, patients were 
fasted throughout the entire three- or four-hour dialysis sessions during the control 
sessions. Fed (meal) and fasted (control) sessions alternated each dialysis session 
throughout the study. For results, a statistically significant decrease in MAP and diastolic 
blood pressure (DBP) in HD patients was observed 30 minutes after the meal. Patients’ 
MAP fell at a rate of 14.4 mm Hg per hour during fed sessions, which was 2.2 mm Hg 
faster than what was observed during the control sessions. Patients’ DBP also fell at a 
faster rate compared to the control sessions (9.9 vs. 2.8 mm Hg per hour). Overall, 
Sherman et al. found 13 episodes of symptomatic hypotension (SH) within 45 minutes 
after meal consumption while finding only 2 during the control sessions. Also, five 
people suffered SH during the meal intervention sessions compared to one during the 
control sessions [81]. In conclusion, Sherman et al. suggested restricting food 
consumption during dialysis to minimize the frequency of hypotensive events in HD 
patients.  
Other evidence found a higher incidence of hypotension after food take during 
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dialysis. Strong et al. conducted an observational study using data from 166 collective 
visits from 23 HD patients [89]. Patients brought their own snacks and food consumption 
in kilocalories and fluid intake was recorded in milliliters, which were divided into high- 
and low-intake categories. The high-intake group consumed more than 200 kcal of food 
and/or 200 mL of fluid during a single treatment. The low-intake group consumed less 
than 200 kcal of food and/or 200 mL of fluid during a single treatment. For results, 32 
hypotensive events were observed in 166 visits along with complaints of cramping and 
there was a need for mannitol to preserve hemodynamic stability in 13 visits. However, 
there were no reports of complaints of nausea, vomiting, and diarrhea. The authors also 
found that the high-intake group had double the incidence of hypotension compared to 
the low-intake group along with a significant difference in the use of mannitol. Lastly, 
patients in the high-intake group were 3 times more likely to experience hypotension and 
5 times more likely to use mannitol with fluid intake of 200 mL or more. However, the 
authors stated that confounding variables such as weight and co-morbidities were not 
controlled or adjusted, which may have led to such results. Therefore, Strong et al. 
indicated that their results do not determine a “cause and effect” relationship between 
eating during dialysis and hypotension, and suggested the provision of individualized 
diets for HD patients instead of completely restricting them from eating during dialysis 
[89]. 
Along with increased hypotensive events due to eating during dialysis, another 
concern that clinicians express is that it could reduce the efficiency of HD because the 
ultrafiltration rate needs to be decreased or stopped when SH is detected in patients. 
Additionally, decreased duration of HD treatment due to SH could lead to higher IDWG, 
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which could exacerbate patients’ risk of hypotension as well as mortality rate. Therefore, 
many clinicians still believe the negative effect of meals provided during dialysis on BP 
in HD patients [43].  
However, findings regarding the effects of food consumption during dialysis on BP 
are inconsistent. In more recent studies, they have shown no change in the frequency of 
SH events in HD patients after eating during dialysis [67, 84]. Additionally, those studies 
emphasized the need to provide high-protein, renal-appropriate meals during dialysis as 
such meals have been shown to have beneficial effects on HD patients’ serum albumin as 
well as their mortality rate.  
A retrospective cross-sectional study conducted by Benaroia et al. examined the 
effect of oral intake of food and fluid during HD treatment and its association with 
hypotension [2]. Three consecutive HD runs in 126 stable HD patients were observed (a 
total of 378 sessions) and hypotension was defined as SBP of less than 100 mm Hg at any 
point during the dialysis treatment. Oral intake was measured in liters and calculated with 
a specific equation: total ultrafiltration – (net weight loss + intravenous fluids given). To 
conclude their findings, they found no correlation between oral intake and SBP, DBP, 
and MAP. When the range for hypotension was expanded to 90, 95, 105, or 110 mm Hg, 
the results remained consistent. Furthermore, BP for the patients who consumed more 
than 0.273 L of oral intake did not differ from the patients who consumed less than 0.273 
L, which supports the safety of provision of meals during dialysis [2].  
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1.3 Oral Nutrition Supplements or Meals during Dialysis in Hemodialysis Patients: 
Effects on Nutritional Status and Clinical Outcomes 
In this section, the advantages and disadvantages of two widely used forms of 
nutrition during dialysis, oral nutritional supplements and meals, and their effects on HD 
patients will be discussed. 
	
1.3.1 Oral Nutritional Supplements 
Considering that an average HD patient consumes less than 1.0 g/kg/day of 
protein, HD patients would need additional 0.2 to 0.4 g/kg/day of protein to meet their 
needs recommended by KDOQI guidelines. Providing oral nutritional supplements 
during HD could help meet these needs [35, 36, 83]. According to KDOQI guidelines, 
patients who are not meeting their energy and protein needs are recommended to take 
oral nutritional supplements during dialysis and the common oral nutritional supplements 
provided include Nepro®, Ensure®, and high-protein energy bars [22]. There has been an 
increasing trend towards allowing and encouraging the use of oral nutritional 
supplements during dialysis as it has been shown to mitigate catabolism during and after 
dialysis treatments, which is evidenced by increasing serum albumin [9, 36, 73].  
A retrospective propensity-matched cohort study conducted by Weiner et al. 
examined the effect of oral nutritional supplementation composed of 15 grams of protein 
in HD patients with less than or equal to 3.5 g/dL of serum albumin [96]. Participants 
with a serum albumin level lower than 3.5g/dL before the initiation of a nutritional 
supplement protocol were eligible to participate and supplements were provided during 
dialysis until their serum albumin level reached and was maintained at 4.0 g/dL. A total 
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of 6,453 MHD patients were eligible to participate and of these, the nutritional 
supplement protocol was prescribed for 2,700, where 1,278 patients were propensity 
matched to controls. The results revealed that adding the nutritional supplement was 
associated with a 29% reduction in the hazard of all-cause mortality. This reduction in 
mortality was also associated with an increase in serum albumin level observed in the 
MHD patients who received supplements. Overall, each 0.5 g/dL increase in serum 
albumin over time was associated with a 66% lower risk of death in this population. 
Therefore, Weiner et al. suggested the use of nutritional supplementation during dialysis 
as it provided a significant beneficial effect on mortality in HD patients. The authors, in 
conclusion, stated that the oral nutritional supplement may disturb the cycle of protein 
and nutrient wasting during dialysis, which may explain the reduction of mortality [96].  
Along with Weiner et al., other evidence shows that providing protein-rich oral 
nutrition supplements during dialysis improves serum albumin level and mortality rate of 
HD patients. A retrospective matched-cohort study conducted by Lacson et al. focused on 
the effect of oral nutritional supplements in hypoalbuminemic (serum albumin ≤ 3.5 
g/dL) MHD patients [56]. As an intervention, intradialytic supplements were given for a 
year or until patient serum albumin level reached 4.0 g/dL or higher. Patients had four 
options of supplements to choose from, which had 14 to 20 grams of protein and 60 to 
425 calories, and one dose of supplement was given per treatment based on patient’s 
preference or product availability. Results showed that MHD patients who received oral 
nutritional supplements had a 34% reduced risk of all-cause mortality compared to MHD 
patients who never received an oral nutritional supplement. This reduction was greater in 
MHD patients with baseline serum albumin ≤ 3.2 g/dL [56]. 
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Oral nutritional supplementation during HD also may be able to prevent the 
progression of wasting by increasing anabolic effects in patients. Rattanasompattikul et 
al. conducted a pilot study in 84 hypoalbuminemic HD patients to determine the effect of 
high-protein oral nutritional supplements with or without the anti-inflammatory appetite 
stimulator, pentoxifylline, on HD patients’ serum albumin [77]. During this double-blind, 
randomized study, MHD patients received 16 weeks of either oral nutritional 
supplements with anti-oxidative properties (8 oz. of Nepro® and 2 oz. of Oxepa®) and 
20 grams of protein, 400 mg of pentoxifylline, the combination of supplement and 
pentoxifylline, or placebo modules with similar taste and volume as supplements. This 
study found that nutritional supplements during HD without pentoxifylline was 
associated with a significant increase in serum albumin level without reports of serious 
adverse events such as gastrointestinal distress in patients. Interestingly, the effect of 
nutrition supplements alone on serum albumin in MHD patients was as effective as 
pentoxifylline itself and the combination [77].  
The effectiveness of nutrition supplements during dialysis is supported by Cheu et 
al., who evaluated the effect of oral nutrition supplements with 13 grams of protein on 
clinical outcomes in HD patients. Patients received 24 cans of Ensure Plus® (Abbott 
Laboratories) each month for a year and serum albumin, hospitalization, and mortality 
were measured. Similar to the findings of Lacson et al., Cheu et al. found that providing 
nutrition supplements during HD reduced hospitalization in the intervention group 
compared with the control group (21% vs. 27%). Additionally, the intervention group had 
increased serum albumin by 0.058 g/dL on average. However, nutrition supplements did 
not reduce mortality rate, unlike the findings of Lacson et al. [13, 58]. Overall, these 
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findings indicate the ability of nutritional supplements to oppose the catabolic effect of 
HD, which could further reinforce the uncontrolled progression of PEW.  
Along with improving nutritional status, high protein supplemental nutrition may 
reduce the risk of inflammation in HD patients. A randomized controlled trial conducted 
by Tomayko et al. studied the effect of oral supplementation during dialysis treatment on 
inflammation, body composition, and physical function in MHD patients [92]. Twenty-
seven grams of protein from either a whey protein, soy protein, or a non-caloric placebo 
powder mixed with four ounces of water were consumed within 15 minutes of the start of 
dialysis treatment for six months. Serum CRP and IL-6, dual-energy x-ray 
absorptiometry, and gait speed and shuttle walk tests were used as markers of 
inflammation, body composition, and physical function respectively. At the end of the 
protein supplementation, relative protein intake was measured, which was higher in HD 
patients who had either whey or soy protein supplements. As no significant difference 
was found between patients that received whey and soy protein, the two groups were 
combined as one protein group for the comparison with the placebo group. IL-6 levels 
were significantly reduced in patients after 6 months of protein supplements. A trend for 
a reduction in CRP level was found but it was not statistically significant. For body 
composition, patients on protein supplements had significantly improved performance in 
gait speed and shuttle walk tests compared to the placebo group. However, no significant 
changes in serum albumin were observed in patients who received protein supplements. 
This may be due to the baseline characteristics of HD patients such as not meeting the 
traditional criteria for malnutrition and having an average serum albumin of 3.95 g/dL 
[92]. In summary, the use of protein supplements is associated with reduced 
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inflammation and improved physical performance in HD patients but further studies are 
needed to confirm the effect of such supplements on the other inflammation markers and 
nutritional status indicators in hypoalbuminemic HD patients.  
Even though results regarding the mortality rate and presence of inflammation in 
HD patients remain inconsistent, it is suggested that consistent provision of high-protein 
nutritional supplements has a strong association with improved serum albumin in HD 
patients based on evidence presented above.  
	
1.3.2 Meals on Dialysis 
Similar to nutritional supplements, there is some evidence that providing meals 
during HD is associated with improved nutritional status in HD patients. It is imperative 
to consider nutrient content of the meal and recommendations set by KDOQI guidelines 
when designing meal plans for HD patients. Meals with higher protein, lower 
phosphorus-to-protein ratio, and lower potassium may be necessary to achieve the 
optimal outcomes in this specific population [68, 69]. Evidence also suggests that along 
with the provision of meals, the use of a multivitamin and/or phosphate binders should be 
considered if needed [36]. Many studies recommend individualizing the nutrition 
prescription for HD patients in order to reach the best clinical outcome, especially 
reaching the target level of serum albumin [2, 6, 36, 89]. However, as mentioned in 
section 1.2.1, eating during dialysis is restricted in most US dialysis centers mainly due to 
concerns over postprandial hypotension and there are still inconsistent findings regarding 
the safety of eating during dialysis. 
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Similar to nutritional supplements, providing meals during HD is associated with 
reduced catabolism in patients. Koontz et al. conducted a pilot study where they provided 
both high-protein meals and phosphate binders during dialysis sessions to examine their 
effect on serum albumin in MHD patients [50]. One-hundred-ten MHD patients with less 
than 4.0 g/dL of serum albumin were recruited. Patients received either the combination 
of lanthanum carbonate (a phosphate binder) and a high-protein diet (50 g of protein, 850 
kilocalories, and phosphorus-to-protein ratio less than 10 mg/g) or a meal box (< 1 g of 
protein and < 50 calories) without phosphate binders for 8 weeks during each HD 
treatment. Patients who received the combination treatment also received nutrition 
counseling in order to maintain high protein intake outside dialysis sessions. Over the 8 
weeks of intervention, patients with the combination treatment had a change in serum 
albumin of greater than or equal to 0.2 g/dL while maintaining a desirable serum 
phosphorus level, 3.5-5.5 mg/dL. Furthermore, patients verbally expressed satisfaction 
about the intervention without reporting side effects such as gastrointestinal distress and 
hypotension. In conclusion, Kootnz et al. suggested that food consumption during HD is 
safe and effective and that food intake during dialysis is associated with better nutritional 
status in HD patient [50]. 
Due to inconsistent findings, the association between food intake during dialysis 
and postprandial hypotension in HD patients is still not clear. Therefore, more studies 
observing the effect of meal composition in HD patients are needed to find the optimal 





Table 1.2 Potential Pros and Cons of Eating during HD 
Potential Pros Potential Cons 
Related to high survival rates Fear of postprandial hypotension 
Mitigate catabolism during and post-
dialysis 
Aspiration 
Better control of dietary intake Potential choking events, infection, spills, 
and pests 
Increased adherence to dialysis Burden on dialysis staff 




 Compared to general population, HD patients have higher energy and protein 
needs while recommended to limit phosphorus, sodium, potassium, and fluid intake. Such 
stringent nutritional recommendations put HD patients at risk for PEW, PDF, and poor 
QoL. Providing nutrition in the form of oral nutritional supplements or meals during 
dialysis may be able to mitigate consequences of malnutrition in HD patients and 
improve their nutritional status and mortality rate. However, concerns over the risk of 
postprandial hypotension in HD patients hinder clinics from implementing such 
approaches. Therefore, we conducted a pilot study to evaluate the effect of high-protein 
meals provided during dialysis to MHD patients on safety related to postprandial 
hypotension, and collected preliminary data on the effects of the intervention on 
nutritional status and QoL outcomes.
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CHAPTER 2.  METHODS 
2.1 Design and Study Participants 
This is a non-randomized, parallel arm study design. The eligibility criteria 
included: 1) any gender; 2) any race; 3) age 18 years or older; and 4) on MHD.  Patients 
with dysphagia that could not be accommodated by texture modifications, who were 
exclusively nil per os requiring tube feeding or parenteral feeding were excluded from 
the study. MHD patients were recruited to participate in this study from a dialysis center 
located in Lafayette, Indiana, from two shifts each consisting of 12 patients. Shifts were 
Monday, Wednesday, Friday (MWF) ~11:00AM-2:00PM and Tuesday, Thursday, 
Saturday (TTS) ~11:00AM-2:00PM. Screening and informed consent was obtained by 
study staff during the week prior to beginning of study. Nineteen patients were enrolled 
in the study (N = 10 MWF and N = 9 TTS). Demographic and medical history 
information was obtained from the Electronic Medical Record System Software, 
PEARL®. Data from January 2016 to May 2016 were collected and analyzed for the 
present report.  MWF shift patients (N = 10) were allocated to the intervention group to 
receive high protein, renal-appropriate meals during dialysis session. TTS shift patients 
(N = 9) were allocated to be in the control group, in which they were asked to participate 
in all aspects of the study protocol except for meals. The control also consisted of a  
“control for interaction”, where patients were greeted by study staff each dialysis 
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session and offered a small amount of hard candies. One participant in the intervention 
group withdrew from the study as she voluntarily discontinued her dialysis treatment 
during week 3. Data from this individual is not included in the present analysis. Data 
collection included two months of retrospective medical record data prior to the 
beginning of the study, one week of baseline data, and 9 weeks of during study data 
(Appendix A). The study was approved by the Purdue University Institutional Review 
Board (IRB). All participants provided written informed consent. 
	
2.2 Study Meals 
High protein, renal-appropriate lunches were given approximately 1 hour after the 
beginning of each patient’s dialysis session. Several meal options with consistent nutrient 
content were available for patients to choose from based on personal preferences. These 
included tuna bowtie salad, chicken salad plate, beef wrap with potato salad, chicken 
breast sandwich, turkey salad, chicken salad sandwich, vegan bowtie salad, and chicken 
lettuce salad (Table 2.2). Meals were designed by research dietitians at Purdue University 
to be high in protein, low in sodium, phosphorus, and potassium. Each meal contained 30 
grams of protein and approximately one-third of other nutrient recommendations based 
on KDOQI guidelines (Table 2.1).  
Table 2.1. Meal Target Nutrient Content Compared with KDOQI Guidelines 
Nutrient Recommendation Guidelines Study Meal Content 
Protein (g) 1.2 g/kg/d 30g 
Energy (kcal) 35 kcal/kg/d 1/3 daily requirement 
Sodium (mg) 2000-3000 mg/d <600-700 mg 
Potassium (mg) 2000-3000 mg/d <600-700 mg 
Phosphorus (mg) 800-1000 mg/d; or 1 mg/g protein <250-350 mg 
Fluid (mL) Fluid output + 1000 mL/d 240 mL (1 cup) 
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The nutrient content of the various meals was designed to closely match the target 
values (Table 2.2). Additionally, the meals were reviewed by the key personnel of the 
study to review their appropriateness for the MHD patients. Energy and protein intake 
relative to body weight for meals was calculated using post-dialysis body weight 
measured on the session before the beginning of the intervention phase of the study. 
Recommendation by the KDOQI guidelines for energy and protein intake per kg body 
weight per day were divided by 3 (assuming 3 evenly distributed meals a day) for 
comparison (presented in Results section).  
On the week of baseline, patients pre-selected the meals they would like to 
receive with the assistance of a Purdue research dietitian. Based on their personal 
preferences, they could choose to receive the same meal or different meals each day. 
Starting Wednesday of the 1st week of the intervention, patients in the intervention group 
received lunch during the dialysis session. Study staff recorded the time when meal was 
delivered and returned. For each meal, a log was kept to record the amount of food 
consumed using subjective assessment in percentage (0, 10, 25, 50, 75, 90, and 100%), 
which was also recorded by study staff. Patients could decline the meal in part or in 
entirety (e.g. if they felt ill or had low appetite). If patients decided to eat, they were 
allowed to refuse any portion of their meal and were not encouraged to eat anything 
beyond their will. 
For participants in the control group, a study staff person visited the center each 
day to greet them and offer them a small quantity of hard candy as a control for increased 
interaction and attention the intervention group received with meals.
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Tuna Bowtie Salad 718 30.4 18.8 109 549 630 324 
Chicken Salad 
Plate 
700 29.6 17 109 504 687 331 
Beef Wrap with  
Potato Salad 
698 30.2 31.2 73.8 628 720* 336 
Chicken Breast 
Sandwich 
701 30.65 31.8 73.85 711 578 288 
Turkey Salad 733 30.05 37 69 694 580 307 
Chicken Salad 
Sandwich 
658 29.4 37.8 48.3 661 416 277 
Vegan Bowtie  
Salad 
772 27.2 36.5 89.2 520 691 363 
Chicken Lettuce 
Salad 
743 30.2 36.7 74.05 693 586 271 























*Over the target value. CHO, carbohydrate; K, potassium; Na, sodium; P, phosphorus; 
PRO, protein. 
 
2.3 Blood Pressure 
Routine BP data was retrieved from PEARL® for each dialysis session 2 months 
prior to baseline and during the 2-month study (25 sessions each). BP measurements were 
recorded automatically every 30 minutes as part of routine care during the dialysis 
session. The primary outcome, SH, was defined as a hypotensive event during dialysis 
that required medical intervention such as turning off ultrafiltration, the injection of 
sodium chloride, or stopping dialysis. Each SH event was recorded by dialysis staff on 
the medical record as “patient symptomatic”. Additionally, average highest SBP (over 25 
dialysis sessions) and average lowest SBP (over 25 dialysis sessions), maximum value of 
the highest SBP (out of all 25 dialysis sessions), and minimum value of the lowest SBP 
(out of all 25 dialysis sessions) were determined from data collected from the medical 
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record. MAP also was calculated from select BP readings: MAP from the lowest and 
highest BP for each patient during each dialysis session were calculated. Both SBP and 
DBP are used to calculate MAP using the equation: !"#$(&	×	)"#)
+
. Then the average 




Monthly routine renal laboratory tests, which include serum albumin, blood urea 
nitrogen, serum creatinine, glucose, serum calcium, potassium, sodium, phosphate, 
chloride, and carbon dioxide, were drawn on either Wednesday or Thursday of the first 
week of the month depending on patient’s shift. Adjusted calcium in mg/d was 
automatically calculated using this equation: [0.8	×(4.0 − 123456378	29:;<46	(=/
?@))] + 85C;<	D29D4;<	(<=/?@),	if patient’s serum albumin level was below 4.0 g/dL. 
For patients with serum albumin levels at or above 4.0 g/dL, the values reported under 
adjusted calcium equal the unadjusted serum calcium values. Glucose was only included 
in the monthly routine renal laboratory tests if a patient had diabetes. The monthly 
laboratory tests prior to the beginning of the study which served as baseline, laboratory 
tests closest to midpoint of study (week 4), and closest to the end of study (week 9) were 
used and the routine laboratory data was obtained from PEARL®. The estimated 
glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal 
Disease Study (MDRD) equation [36] to assess residual renal function:	175	×
	 8326?2C?4I5?	85C;<	DC52346465 JK.KLM	×	(2=5	46	N52C8)JO.&O+	×
	0.742	 4Q	Q5<295 	×	1.210	 4Q	RQC4D26	R<5C4D26 . An additional 4 mL of blood was 
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drawn for pre-albumin at the same time as the routine monthly blood draw. However, the 
additional blood draw for pre-albumin for mid-study occurred a week before the routine 
monthly blood draw. The obtained blood samples were sent to a commercial laboratory 
(Mid America Clinical Laboratories (MACL), Indianapolis, IN) for pre-albumin analysis. 
If patient was absent on a scheduled blood draw day, monthly routine renal labs and 
additional blood for pre-albumin were drawn on the closest day feasible when patient was 
present at dialysis. Similar to BP data, an additional 2 months of the routine lab data prior 
to the beginning of the study were obtained from PEARL®. Pre-albumin data prior to the 
study are not available, as this is not a routine measure.  
	
2.5 Dialysis Compliance 
The number of dialysis sessions attended during study period was compared 
between the control and the intervention group along with historical attendance over the 2 
months prior to the study (25 sessions each). Additionally, the number of dialysis 
sessions in which patients signed off early (left prior to their designated time) was 
recorded from the same periods. This data was obtained from PEARL®. 
	
2.6 Body Weight and Interdialytic Weight Gain 
Body weight in kilograms was measured routinely pre- and post-dialysis and 
recorded in PEARL® by dialysis staff. Similar to other data, patients’ pre-dialysis and 
post-dialysis body weight data from 2 months prior to the beginning of the study were 
also collected. IDWG was calculated as the weight gained from the end of the previous 





Questionnaires were administered by study staff during the dialysis sessions as 
described below. Study staff instructed patients on filling out the questionnaires and 
assisted if needed. If desired, patients could take the questionnaires home to complete and 
return them to study staff when feasible. Questionnaires were spread over several 
consecutive days, if needed, in order to ease burden of participation on the subjects. 
Spanish versions were available for Spanish-speaking patients and a translator was 
available as needed.  
2.7.1 SF-36v2 Questionnaire 
The SF-36v2 questionnaire (QualityMetric Inc., Lincoln, RI) is a short-form 
HRQOL scoring system with 36 items, which includes 8 independent scales that are then 
summarized into 2 dimensions: physical health and mental health. It has been widely 
used and validated in MHD patients to assess their QoL [32]. The SF-36v2 was 
administered at baseline, mid-study (week 4), and end of study (week 9) to assess 
patient’s QoL. It was administered on paper approximately 60 minutes before the end of 
dialysis session. The scoring of the SF-36v2 was conducted using Health Outcomes 
Scoring Software, version 5.0.  
2.7.2 “Appetite, Mood, and Symptoms” Questionnaire 
The “Appetite, Mood, and Symptoms” questionnaire was a study-specific 
questionnaire administered on a weekly basis including baseline and the end of study to 
assess PDF, hunger and satiety, patient satisfaction, and other study-specific components 
(Appendix B). Responses were made on a visual analog scale. It was administered on 
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paper approximately 30 minutes before the end of dialysis session. Patient responses 
were measured in centimeters, in duplicate using the same ruler (Not at all = 0 cm; 
extremely = 10 cm), and the average value of the duplicate measure was used. For data 
analyses, responses from baseline were compared to the averaged responses from the 9 
weeks of intervention.  
2.7.3 MOS 12-Item Sleep Questionnaire 
The MOS 12-item Sleep questionnaire (QualityMetric Inc., Lincoln, RI) was 
administered at baseline, mid-study (week 4), and end of study (week 9) to assess 
patients’ sleep quality. It was administered on paper approximately 60 minutes before the 
end of dialysis session. The scoring of the MOS 12-item Sleep questionnaire was 
conducted using Health Outcomes Scoring Software, version 5.0. 
 
2.7.4 “End of Study” Questionnaire 
The “End of Study” questionnaire is a study-specific instrument which was 
administered at the end of study (week 9) to assess patients’ attitudes and perceptions of 
nutrition and receiving meals on dialysis (Appendix C). It was administered as an add-on 
to the “Appetite, Mood, and Symptoms” questionnaire only during the final week of the 
study. It was administered on paper approximately 30 minutes before the end of dialysis 
session. Responses were recorded on a 5-point Likert scale.  
	
2.8 Adverse Events 
An adverse event was defined as “any untoward medical occurrence in a subject 
during participation in the clinical study.”  Abnormal or adverse signs, symptoms, and 
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abnormal assessment including laboratory test value, vital signs, or any combination of 
those were recorded and reported to the principal investigator of this study and Purdue 
University IRB. The principal investigator of this study completed an Adverse Event 
Report Form for every adverse event as was notified. Similar to adverse events, serious 
adverse events such as death, a life-threatening event, inpatient hospitalization or 
prolongation of existing hospitalization, a persistent or significant disability/incapacity, a 
congenital anomaly or birth defect, and an important medical event based upon 
appropriate medical judgements are recorded and reported as well. Adverse event 
reporting followed the Purdue University IRB guidelines. 
	
2.9 Data Management and Statistical Analyses 
 Data obtained from medical records were recorded directly into REDCap, as were 
data generated specifically for the study. Statistical Analysis Software (SAS), version 9.3 
(SAS Institute Inc., Cary, NC) was used to perform all statistical testing. The primary 
outcome, SH events, as well as other frequency data (dialysis session attendance) were 
assessed as the difference in frequency between pre-study and during study in each 
group, using Wilcoxon signed-rank test (paired data); and the difference in change in 
frequency from pre-study to during-study between groups by Wilcoxon rank sum test 
(unpaired data). Other outcomes were assessed using repeated-measures ANOVA with 
fixed effects for group, time, and group × time interaction, and subject nested within 
group as a random effect. Assumptions for normal distribution and constant variance of 
residuals were checked prior to data analyses. Planned Tukey’s post-hoc pairwise 
comparisons included: 1) between different time-points within a group, and 2) between 
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the same time-points between groups were evaluated when the overall ANOVA showed a 




CHAPTER 3. RESULTS 
3.1 Demographics and Baseline Characteristics 
Nineteen HD patients were consented during the baseline week of the study. One patient 
withdrew from the study due to discontinuation of dialysis. For data analyses, a total of 
18 patients, N = 9 in intervention and N = 9 in control group, who completed the 9-week 
intervention, were included. 55% (N = 10) of patients in this study were female and the 
majority (N = 14) was Caucasian. The mean age of patients was 62.44 ± 15.93 years old 
and the mean BMI was 32.65 ± 9.01 kg/m2, which is classified as class 1 obesity category 
[22].  The eGFR was 8.0 ± 3.24 mL/min/1.73 m2, and patients were on dialysis for a 
mean of 3.35 ± 2.64 years. The primary etiologies of ESRD in these patients were 
diabetes mellitus (N = 9), hypertension (N = 2), others (glomerulonephritis, polycystic 
kidneys, and myeloma) (N = 3), and unspecified/unknown (N = 4). The mean baseline 
serum albumin was 3.84 ± 0.33 g/dL and mean normalized protein catabolic rate was 
1.04 ± 0.28 g/kg , which is the common parameter used in dialysis centers to assess 
dietary protein intake in HD patients [22].  Most baseline characteristics were similar 
between groups as indicated by P-values greater than 0.05 (Table 3.1). However, blood 
urea nitrogen and phosphate levels were significantly higher (P = 0.032 and P = 0.04, 
respectively) and carbon dioxide significantly lower (P = 0.044) in the control group 




Table 3.1. Baseline Characteristics of Participants 









Age (Years) 62.44 ± 
15.93 
66.78 ± 11.40 58.11 ± 19.15 - 0.26 
Female 10/18 5/9 5/9 - - 





   Underweight 
   Healthy 
   Overweight 
   Obese Class I 





































   Diabetes 
   Hypertension 
   Others 


























Time on Dialysis 
(Years) 
3.35 ± 2.64 3.08 ± 1.96 3.61 ± 3.28 - 0.68 
eGFR 
(mL/min/1.73m2) 
8.0 ±  
3.24 
7.88 ± 2.89 8.11 ± 3.72 ≥ 60 18 ** 0.89 






9.29 ± 0.69 9.14 ± 0.53 9.43 ± 0.82 8.4 – 9.5 22 0.39 
Albumin (g/dL) 3.84 ± 0.33 3.76 ± 0.35 3.93 ± 0.29 ≥ 4.0 22 0.26 
BUN (mg/dL) 53.06 ± 
16.79 



















7.01 ± 2.34  
 
 
6.7 ± 1.44 
 
 
7.32 ± 3.05 
0.5 – 1.5 
for men;   










29.78 ± 13.20 27.11 ± 12.48 25 – 35 71 0.67 
Phosphate 
(mg/dL) 
5.86 ± 1.69 5.04 ± 0.97 6.68 ± 1.91 3.5 – 5.5 22 0.04* 
Potassium 
(mEq/L) 




Table 3.1 continued 









Sodium (mEq/L) 139.11 ± 
2.22  
139.22 ± 2.22 139 ± 2.35 135 – 145 
22 
0.84 













64.89 ± 30.18 65.78 ± 38.24 60 – 170 28 0.96 
Total Protein 
(g/dL) 
6.76 ± 0.51 6.71 ± 0.46 6.81 ± 0.59 6.0 – 8.3 64 
** 
0.69 
Data are represented as mean ± standard deviation (SD).  BMI, body mass index; BUN, 
blood urea nitrogen; eGFR, estimated glomerular filtration rate; nPCR, normalized 
protein catabolic rate; P, P-values; TIBC, total iron binding capacity. *P < 0.05. **Based 
on healthy population. 
 
3.2 Meal Characteristics and Compliance 
The mean nutrient content of all meals provided are shown in Table 3.2. These 
include calories from beverages provided during the meal. Overall nutrient content of the 
meals was within the targeted values. Average energy and protein in grams provided per 
kilogram body weight are shown in Table 3.3.  








Actual Content ± SD 
Kcal from 
Macronutrients  
(% of Total 
Kilocalories) 
Total Kcal 800 715.38 ± 34.48 - 
Protein (g) 30 g 29.71 ± 1.09 118.85 
(16.51%) 
Fat (g) - 30.85 ± 8.37 277.65 
(38.58%) 
CHO (g) - 80.78 ± 20.70 323.1  
(44.90%) 
Na (mg) < 600-700 620 ± 83.95 - 
K (mg) < 600-700 595.43 ± 92.68 - 
P (mg) < 250-350 312.125 ± 32.05 - 
Fluid (mL) 240  240 - 
Data are represented as mean ± SD. CHO, carbohydrate; K, potassium; Kcal, 




Table 3.3. Energy (kcal) and Protein (g) per kilogram Body Weight Provided per 
Meal 
Subject Number Energy by Body Weight 
(kcal/kg) 
Protein by Body Weight 
(g/kg) 
 
101 7.00 ± 0.34  0.29 ± 0.01  
102 10.63 ± 0.51 0.44 ± 0.02 
103 7.11 ± 0.34 0.30 ± 0.01 
104 10.43 ± 0.50 0.43 ± 0.02 
105 9.83 ± 0.47 0.41 ± 0.02 
106 6.69 ± 0.32 0.28 ± 0.01 
107 9.02 ± 0.43 0.37 ± 0.01 
108 10.50 ± 0.51 0.44 ± 0.02 




(6.69 - 10.63) 
0.37 ± 0.07 
(0.28 – 0.44) 
KDOQI 
Guidelines 
Translated to per 
Meal* 
10-12 kcal/kg/meal 0.4 g/kg/meal 
Data are represented as mean ± SD.*Assuming a meal pattern of three meals a day with 
evenly divided energy and protein, the KDOQI guidelines of 1.2 g/kg/day of protein and 
30-35 kcal/kg/day of energy translate to 0.4 g/kg/meal of protein and 10-12 kcal/kg/meal 
of energy. Body weights are actual dry body weights at baseline, or adjusted dry body 
weight for patients with actual dry body weights > 115% or < 95% of ideal body weight 
as described in the KDOQI guidelines [22]. 
 
In 78.67% of 225 meals provided, at least 50% of the main items were consumed. 
In 63.11% of 225 meals provided, at least 75% of the main items were consumed.  
	
3.3 Frequency of Symptomatic Hypotensive Events and Blood Pressure Outcomes 
In the intervention group, there were 4 SH events observed in 3 patients over 25 
dialysis sessions prior to the initiation of study, and 12 SH events in 4 patients over 25 
dialysis sessions during study (Table 3.4). In the control group, there was 1 SH event in 1 
patient over 25 dialysis sessions prior to the initiation of study, and 5 SH events in 4 




frequency from pre-study to during study was not statistically significant for either group 
(P = 0.25 for intervention; P = 0.313 for control). Change in the frequency of SH events 
from pre-study to during study was also not different between the intervention and 
control groups (P = 0.9067).  
Table 3.4. Number of SH Events in the Intervention Group 
Subject Pre-Study During Study Change 
101 2 2 0 
102 1 0 -1 
103 0 0 0 
104 0 0 0 
105 0 3 3 
106 0 3 3 
107 0 0 0 
108 0 0 0 
110 1 4 3 
Total 4 12 8 
 
Table 3.5. Number of SH Events in the Control Group 
Subject Pre-Study During Study Change 
231 0 0 0 
232 0 2 2 
233 0 1 1 
234 0 1 1 
235 0 0 0 
236 0 0 0 
237 1 0 -1 
238 0 1 1 
239 0 0 0 
Total 1 5 4 
 
Over 25 sessions, the control group had higher average lowest MAPs compared to 
the intervention group both pre- and during study as indicated by the significant effect of 





Repeated measures ANOVA revealed a significant group effect for average 
highest SBP, average lowest SBP, and average highest MAP where values were lower in 
the intervention group compared with the control group (Table 3.6). However, there was 
no effect of time (i.e. no difference between pre-study and during study) and no group × 
time interaction. There was a significant effect of group for the maximum value of the 
highest SBP; values were higher in the control group compared with the intervention 
group. But, there was no effect of time and no group × time interaction. In contrast, there 
was no significant group effect for the minimum value of the lowest SBP, in addition to 
no time effect or group × time interaction. For maximum value of the highest MAP and 
minimum value of the lowest MAP, no effect of group, time, or group × time interaction 
was found. 
Figure 3.1. Comparison of the Average Lowest MAP between Groups and Time 
Periods
	




































Table 3.6. Additional Blood Pressure Outcomes in the Intervention and Control 
Groups 





































































































































































































































Data are represented as mean ± SD. *P < 0.05. 
 
	
3.4 Nutritional Status Indicators and Other Biochemistries 
One patient from the control group was excluded from these data analyses as he 
was not present at dialysis for one of the monthly routine renal labs due to hospitalization 
unrelated to the study. Overall, for serum albumin, there were no significant effects for 
group (P = 0.398), time (P = 0.307), or group × time interaction (P = 0.466).  
 Baseline pre-albumin samples were collected; however, the commercial 
laboratory discarded the samples without analyzing. Thus, only mid-study and end-of-
study values are reported. There was a significant effect of group and time for pre-
albumin, where the control group had higher values compared with the intervention 
group (P = 0.017), and end of study values were lower than mid-study values in the 
control group only (P = 0.047). The group × time interaction did not reach statistical 
significance (P = 0.12); however, the significant effect of time appears to be driven by 
the control group: Tukey post-hoc pairwise comparisons show a near significant 
difference between mid-study and end of study in the control group (P = 0.07), but no 










Figure 3.2. Mean Serum Albumin in Both Groups Measured at Baseline, Mid-
Study, and at the End of Study.  
 
Error bars represent SEM. No significance was found. 
	
Figure 3.3 Mean Pre-albumin in Both Groups Measured at Mid-Study and at the 
End of Study. 
	





























































Table 3.7. Average Renal Laboratory Test Values 
 Intervention Control ANOVA – P-Values 


































































































































































































































































































Data are represented as mean ± SD. BL, baseline; BUN, blood urea nitrogen; Cr, 
creatinine; EOS, end of study; K, potassium; MP, midpoint; nPCR, normalized protein 
catabolic rate; PO4, phosphate; TIBC, total iron binding capacity. *P < 0.05. 
 
Repeated measure ANOVA revealed a significant effect of group for adjusted 
calcium, total iron, phosphate, creatinine, blood urea nitrogen, and normalized protein 
catabolic rate, where the values were lower in the intervention group compared with the 
control group (Table 3.7).  However, there were no time effects (i.e. no difference 
between pre-study and during study) or group × time interactions for any of these 
measures. Carbon dioxide, on the other hand, had a significant effect of group and time 
(P = 0.005 and P = 0.039, respectively), with no interaction effect (p = 0.577), showing 
that carbon dioxide was significantly higher in the intervention group compared with the 
control group and at baseline compared with the end of study.  Similar to carbon dioxide, 
total iron binding capacity had significant effect of group and time (P < 0.0001 and P = 
0.007, respectively), with no interaction (P = 0.44), showing that values were higher in 
the control group compared with the intervention group and at the end of study compared 
with baseline. A significant effect of time was found for sodium, where values were 
higher at mid-point compared with baseline (P = 0.047) but effects for group and group × 
time interaction were not found (P = 0.635 and P = 0.233, respectively).  
	
3.5 Dialysis Compliance 
Out of 25 dialysis sessions, the mean number of absences for intervention was 
3.111 ± 5.159 dialysis sessions and 1.333 ± 1.581 dialysis sessions for control prior to the 
initiation of study. Out of 25 dialysis sessions observed during study, the mean number of 




sessions for controls. Change from pre-study to during study in the number of absence 
was not different between the intervention and control groups (P = 0.2543). Providing 
high-protein meals during dialysis did not significantly affect the number of absences (P 
= 0.375) (Table 3.8).  Similar to the intervention group, no significant change in absences 
was observed in the control group (P = 0.688) (Table 3.9).  
Table 3.8. Number of Absences in the Intervention Group 
Subject Pre-Study During Study Change 
101 0 0 0 
102 1 1 0 
103 8 1 -7 
104 0 0 0 
105 15 2 -13 
106 0 1 1 
107 3 3 0 
108 1 0 -1 
110 0 0 0 
Totals 28 8 -20 
 
 
Table 3.9. Number of Absences in the Control Group 
Subject Pre-Study During Study Change 
231 3 7 4 
232 1 0 -1 
233 1 3 2 
234 0 0 0 
235 4 5 1 
236 0 0 0 
237 3 1 -2 
238 0 0 0 
239 0 0 0 
Totals 12 16 4 
 
3.6 Interdialytic Weight Gain 
Repeated measure ANOVA revealed a significant effect of time on IDWG, where 




period (25 dialysis sessions). There also was a significant effect of group × time 
interaction for IDWG as shown in Table 3.10, where the intervention group had lower 
IDWG during study compared with pre-study period (P = 0.016). 
Table 3.10. Average Interdialytic Weight Gain in Both Groups 


























0.588 0.008* 0.016* 
 
3.7 Quality of Life 
One patient in the intervention group was excluded from data analyses for all 
questionnaires as she declined to complete them. From the “Appetite, Mood, and 
Symptoms” questionnaire, a significant effect of group for hunger, physical fatigue, and 
sleepiness was found, where values were higher in the control group compared with the 
intervention group at the end of dialysis treatment (P = 0.006, P = 0.006, and P = 0.037, 
respectively). Similarly, self-reported fullness, desire for salty foods, hand grip strength, 
and ability to concentrate also had a significant effect of group (P = 0.008, P = 0.013, P = 
0.002, and P = 0.011, respectively), but values were lower in the control group compared 
with the intervention group at the end of dialysis treatment. However, no effect of time 
and group × time interaction was found for any of those factors except for physical 
fatigue, hand grip strength, and ability to concentrate, which had a significant effect of 
group × time interaction (P = 0.004, P = 0.049, and P = 0.042, respectively). Repeated 
measures ANOVA revealed a significant effect of time for thirst and mental fatigue (P = 




with the average of 9 responses gathered during study, but there was no effect of group 
and group × time interaction. Level of irritability also had a significant effect of time (P = 
0.005) but the values were higher during study compared with baseline. However, no 
effect of group and group × time interaction was found for thirst, mental fatigue, and 
level of irritability (Table 3.11). 
Table 3.11. Responses for the “Appetite, Mood, and Symptoms” Questionnaire 























0.006* 0.415 0.906 








0.008* 0.355 0.322 



















0.287 0.398 0.197 























































































0.006* 0.351 0.004* 








0.037* 0.157 0.09 








0.235 0.66 0.342 












Table 3.11 continued 

























0.146 0.328 0.317 








0.352 0.932 0.595 


































































































0.508 0.498 0.199 
Data are represented as mean ± SD. BL, baseline; EOS, end of study; MP, midpoint;  
*P < 0.05. 
 
From the SF-36v2 questionnaire, repeated measures ANOVA revealed a significant 
effect of group for physical functioning, role physical, bodily pain, general health, mental 
health, physical component summary, and mental component summary components, 
where the values were higher in the intervention group (P = 0.006, P = 0.006, P = 0.015, 
P = 0.03. P < 0.0001, P = 0.014, and P = 0.031, respectively). However, no effect of time 






Table 3.12. Scores for Each Component in the SF-36v2 Questionnaire 




































































































































































































































0.031* 0.806 0.411 
Data are represented as mean ± SD. BL, baseline; BP, bodily pain; EOS, end of study; 
GH, general health; MCS, mental component summary; MH, mental health; MP, 
midpoint; PCS, physical component summary. PF, physical functioning; RE, role-
emotional; RP, role-physical; SF, social functioning; VT, vitality. *P < 0.05. 
 
Repeated measure ANOVA revealed a significant effect of group for sleep 
disturbance, short of breath, sleep problems Index I, and sleep problems Index II 
components on the MOS 12-Item Sleep questionnaire (P = 0.009, P < 0.0001, P = 




compared with the control group except for the sleep problems Index II component. 
However, no time effects or group × time interactions were found for any of these 
components (Table 3.13). 
Table 3.13. Scores for Each Component in the MOS 12-Item Sleep Questionnaire 




































































































































































0.002* 0.194 0.825 
Data are represented as mean ± SD. BL, baseline; DW, drowsiness; EOS, end of study; 
MP, midpoint; SA, sleep adequacy; SD, sleep disturbance; SN, snoring; SOB, short of 
breath; SPI-I, sleep problems index I; SPI-II, sleep problems index II. *P < 0.05. 
 
3.8 Adverse Events 
A total of 10 patients were hospitalized throughout the study (N = 5 in each group). 
All hospitalizations were unrelated to the study. One patient in the intervention group 




decline meals twice. One patient vomited during the meal due to sickness where as 
another vomited during the meal due to consistency of food. Gastrointestinal distress, or 
general stomach upset, also was commonly reported by HD patients (N = 5 in the 
intervention group) prior to the initiation of dialysis treatment. 
	
3.9 Patient Attitudes toward Nutrition and Meals during Dialysis at the End of Study 
17 patients completed the EOS questionnaire during the last week of intervention 
while one patient in the intervention group declined to complete it. Overall, both groups 
showed positive attitudes toward receiving nutritious meals during dialysis and no 
differences in responses were found between groups (Figure 3.4). When patients were 
asked question 1: “how easy do you feel it is for you to eat nutritiously or follow a renal 
diet?”, the mean responses from patients in the intervention and control groups were 3.13 
± 1.46 and 2.56 ± 1.51 respectively, where 1 = very difficult, 2 = somewhat difficult, 3 = 
neither difficult nor easy, 4 = somewhat easy, and 5 = very easy and 35% responded with 
“somewhat easy” or “very easy”. The difference in responses between groups was not 
statistically significant (P = 0.44). When patients were asked question 2: “how interested 
would you be in receiving nutritious meals during dialysis?”, both groups showed a 
moderate interest in receiving renal-appropriate meals during dialysis based on their 
mean responses, 3.5 ± 1.31 for intervention and 3.44 ± 1.42 for control where 1 = not at 
all interested, 2 = somewhat disinterested, 3 = neither interested nor disinterested, 4 = 
somewhat interested, and 5 = very interested and 71% responded with “somewhat 
interested” or “very interested”. The mean responses for this question was not different 




you be in a meal delivery service (to your home)?”, patients in the control group showed 
more interest than the intervention group (3.56 ± 1.33 and 2.38 ± 1.19, respectively) and 
47% responded with “somewhat interested” or “very interested”. But the difference 
between groups only had a marginal trend for significance (P = 0.07). For question 4: 
“how important are price, taste, convenience, and taste for you in deciding what to eat?” 
(1 = very unimportant, 2 = somewhat unimportant, 3 = neither important nor 
unimportant, 4 = somewhat important, and 5 = very important), patients in the 
intervention groups responded 3.375 ± 0.132 for price, 4.75 ± 0.463 for taste, 3.625 ± 
1.302 for convenience, and 4.125 ± 0.991 for taste. Patients in the control group showed 
similar response to question 4 compared to the intervention group: 3.222 ± 1.481 for 
price, 4.222 ± 0.972 for taste, 4.333 ± 0.5 for convenience, and 4.222 ± 0.833 for 
nutrition (P = 0.82 for price, P = 0.17 for taste, P = 0.18 for convenience, and P  = 0.83 
for nutrition). Overall, taste, convenience, price, and nutrition of meals were rated as 













Figure 3.4. Patient Attitudes on Nutrition and Meals during Dialysis after 9-Week 
Intervention.  
Error bars represent SEM. P-values are for differences between groups. Q1 = “how easy 
do you feel it is for you to eat nutritiously or follow a renal diet?”; Q2 = “how interested 
would you be in receiving nutritious meals during dialysis?”; Q3 = “how interested 






















P = 0.44 
P = 0.93 P = 0.07 P = 0.82 
P = 0.17 





CHAPTER 4. DISCUSSION 
PEW is one of the risk factors that increases mortality in HD patients [25] To 
avoid PEW and its related consequences, meeting nutrient recommendations set by 
KDOQI may be beneficial. Studies suggest that providing either oral nutritional 
supplements or renal-appropriate meals during dialysis may be effective at helping HD 
patients to meet nutrient needs but some studies question the safety of this approach 
related primarily to postprandial hypotension [81, 89]. Therefore, our study investigated 
the effect of high-protein, renal-appropriate meals given during dialysis in HD patients on 
BP outcomes.   
The aims of this study were to produce preliminary data on the effect of providing 
high-protein, renal-appropriate meals during dialysis on the primary outcome of SH 
events, and secondary outcomes of other BP measures, patients’ QoL, PDF, dialysis 
compliance, hunger/satiety, fluid control, electrolyte control, and nutritional status. We 
hypothesized that patients in the intervention group, who received high-protein, renal-
appropriate meals during dialysis would 1) not have increased number of SH events on 
dialysis, and 2) have better nutritional status, electrolyte balance, dialysis compliance, 




meals during dialysis do not increase the frequency of SH events. Patients in the 
intervention group generally consumed at least half of the meals provided as indicated by 
these findings: in 78.67% of 225 meals provided, at least 50% of the main items were 
consumed and in 63.11% of 225 meals provided, at least 75% of the main items were 
consumed. Also, a decrease in IDWG was observed in the intervention group. However, 
improvements in nutritional status indicators, electrolyte balance, and dialysis 
compliance were not observed in the intervention group that received high-protein, renal-
appropriate meals during dialysis for 25 sessions. 
 Our results support our main hypothesis that providing high-protein meals during 
dialysis does not affect BP of HD patients. Primarily, an increase in the frequency of SH 
events was not observed in either group. Second, neither group had any significant 
differences in average highest or lowest SBP during study compared with the pre-study 
period. Similarly, the maximum value of the highest session SBP and the minimum value 
of the lowest session SBP remained similar during study compared with pre-study in both 
groups. Lastly, the average lowest MAP during study was similar to values from the pre-
study period in both groups. There were, however, overall group differences in BP 
measures: the control group had significantly higher average highest SBP, average lowest 
SBP, maximum value of the highest SBP, average highest MAP, and average lowest 
MAP than the intervention group, which suggests that the control group may have be less 
vulnerable to increased frequency of SH events and low BP. Conversely, the intervention 
group may have been more vulnerable to SH events and low BP. But, our findings show 




the frequency of SH events in either group, despite differences between groups in 
baseline measures.  
 Our findings are supported by some studies in the literature, and contradicted by 
others. A study conducted by Benaroia et al. examined the effect of oral nutrition intake 
during dialysis on hypotensive events [2]. Benaroia et al., however, defined hypotension 
as SBP < 100 mm Hg while we defined hypotension based on patients’ need for medical 
intervention due to symptoms they experience. Also, they observed 3 consecutive dialysis 
sessions in 126 hemodynamically stable HD patients. Despite these differences in study 
design, results by Benaroia et al. were consistent with our study: oral intake was not 
predictive of hypotension. Even when Benaroia et al. changed the definition of 
hypotension to SBP less than 90, 95. 105, or 110 mm Hg, results remained the same. 
However, these authors concluded the duration of HD patients observed was too short to 
determine the effect of eating during dialysis on their overall BP status.   
 In contrast, Sherman et al. conducted a study observing the effect of standard 
meals (two slices of white bread, two ounces of low sodium turkey breast, one teaspoon 
of regular mayonnaise, a slice of pound cake, and four ounces of cranberry juice cocktail) 
given during dialysis on BP of nondiabetic HD patients [81]. This study was similar to 
our study because HD patients were given meals during dialysis while focusing on its 
effect on the frequency of SH events during dialysis. However, their results showed a 
significant increase in frequency of SH events with meals: 2 out of 63 sessions during 
control compared with 13 out of 62 sessions with feeding, and in 1 out of 9 patients 
during control and 5 out of 9 patients during feeding. Additionally, DBP and MAP fell 




according to Sherman et al. Their significant findings related to BP differed from our 
study, which showed no significant effect of meals on SH or other BP outcomes. The 
statistical approaches for evaluating the frequency of SH in the study by Sherman et al. 
were not described. However, it appears that a Chi-squared test was performed. If our 
results were similarly analyzed by Chi-squared with 4 out of 9 patients in the intervention 
group with a SH event, and 3 out of 9 patients in the control group with a SH event, we 
still see a non-significant difference in frequency (P = 0.629). However, one can see that 
the difference between our non-significant Chi-squared test and Sherman et al.’s 
significant results is a matter of only 1 fewer patient in the intervention group with SH 
events and two more control patients with SH events.  However, our chosen statistical 
approach is stronger as it pairs data from pre-study to during study within the same 
subject. Our study also includes more dialysis sessions where meals were given (25 
sessions per patient, compared with an average of only 13 sessions per patient in the 
Sherman et al. study).  Given the discrepancy in BP findings between studies, additional 
studies with larger sample size and longer duration may be necessary to more definitively 
assess the effect of meals on dialysis on BP in HD patients. Furthermore, future studies 
should investigate if different nutrient content of meals affects BP response in HD 
patients as high carbohydrate meals have been shown to decrease BP in elderly patients 
[94]. 
Serum albumin did not change over time in either the intervention or control 
group. Considering the half-life of albumin, however, these results were anticipated. Yet, 
some studies observed significant increase in serum albumin in patients who received 




propensity-matched cohort study where they provided 15 g of protein during dialysis in 
forms of liquid oral nutritional supplements to 2,700 MHD patients with ≤ 3.5 g/dL of 
serum albumin [96]. Patients were given oral nutritional supplements until their serum 
albumin reached ≥ 4.0 g/dL and/or if their serum albumin dropped below 4.0 g/dL. 
Unlike our results, they found a significant increase in serum albumin, 0.006 g/dL per 
month, in MHD patients at the 10th month since the initiation of the oral nutritional 
supplements protocol. Along with a significant increase in serum albumin, a significant 
improvement in mortality of MHD patients was observed as they reported that each 0.5 
g/dL increase in serum albumin over time was associated with a 66% lower risk of death. 
However, baseline serum albumin of our patients, 3.84 ± 0.33 g/dL, was higher and the 
duration of our study was shorter than the study conducted by Weiner et al. Therefore, 
these factors may have limited our ability to detect an effect on serum albumin.  
Pre-albumin is similar to albumin as it is considered a negative acute phase 
reactant; therefore, it is sensitive to presence of inflammation. However, its half-life is 
shorter than albumin, meaning that it may be able to more acutely detect changes in 
individual’s nutritional status. Moreover, according to Rambod et al. low serum pre-
albumin (< 20 mg/dL) and a drop (≥ 10 mg/dL) in pre-albumin over 6 months is 
associated with death risk even in HD patients with serum albumin ≥ 3.5 g/dL [75]. 
Regardless of its reliability as a nutritional status indicator and predictor of mortality, 
however, there is insufficient amount of evidence regarding the effect of eating during 
dialysis on pre-albumin in HD patients. Therefore, pre-albumin was added as another 
nutritional status indicator in our study. Our results showed that the level of pre-albumin 




while the intervention group had consistent level of pre-albumin throughout the study. 
However, because baseline pre-albumin samples were unfortunately discarded without 
analyzing, it is difficult to conclude if meals during dialysis induced a significant impact 
on pre-albumin in HD patients especially after the initiation of meal intervention. 
Additionally, inflammation markers were not included in data collection and analyses, 
which may have helped in interpreting the nutritional status measures of albumin and pre-
albumin. Indeed, some previous studies have shown effects of protein on inflammation in 
dialysis patients. Tomayko et al. conducted a randomized controlled trial to study the 
effect of oral nutritional supplements on inflammation markers, physical function, and 
body composition in MHD patients [92]. Thirty-eight patients were given either 27 g of 
whey protein, soy protein, or non-caloric placebo powder with 4 oz. of water. Oral 
nutritional supplements were consumed within 15 minutes of the initiation of dialysis 
treatment for 6 months. Prior to the beginning of this study and at the end of the 6-month 
intervention, markers of inflammation (CRP and IL-6), body composition, and physical 
function were measured then compared. Tomayko et al. did not find significant 
differences between protein sources during data analyses; therefore, patients who 
received whey and soy supplements were combined into one “protein” group. For results, 
6 months of protein supplementation significantly reduced IL-6 in the “protein” group 
compared with the control group that received non-caloric placebo powder. For CRP 
levels, however, no significant decrease was found. Yet, Tomayko et al. still found that 
the change in CRP levels was positively associated with the change in IL-6 levels over 
the intervention period. Physical function also significantly improved in the intervention 




improvement in body composition after the 6-month intervention period. Thus, 
considering characteristics of negative acute phase reactants, a mechanism behind a 
significant decrease in pre-albumin from mid-study to the end of study in the control 
group is not clear. Future studies should consider 1) patients’ baseline serum albumin 
level, as higher level may attenuate the effect of high-protein meals, and 2) the presence 
of inflammation for better interpretation of the negative acute phase reactant nutritional 
status markers throughout the study.   
Overall, no improvements with the intervention in renal laboratory values and 
dialysis compliance were found throughout the study. However, this may be due to the 
short duration of the study. In contrast, there was a significant decrease in IDWG in the 
intervention group. This has at least two competing explanations: 1) meals resulted in 
better fluid control evidenced by a lower IDWG, or 2) meals resulted in less efficient 
fluid removal during dialysis so that post-dialysis body weight was not as low.  Further 
investigation of plasma sodium levels to assess fluid status in each dialysis session would 
be beneficial in parsing this result. Our study found slightly lower plasma sodium at mid-
study compared with the baseline while plasma sodium at the end of study remained 
consistent with the baseline in both groups. Thus, the decrease in IDWG in the 
intervention group did not correspond with a decrease in plasma sodium, supporting the 
interpretation that the difference in IDWG is indicative of better fluid control, rather than 
decrease of dialysis fluid removal efficiency.  
Results for QoL were inconsistent as different questionnaires showed varying 
results. Based on the “Appetite, Mood, and Symptoms” questionnaire, subjective self-




significantly in the control group compared with the intervention group. The severity of 
physical fatigue also significantly worsened in the intervention group while showing a 
significant improvement in the control group. Yet, based on the SF-36v2 questionnaire, 
there was a trend for an interaction in physical functioning component, where the 
intervention group showed an improvement compared with the control group. The MOS 
12-Item Sleep questionnaire showed no change in sleep quality after the 9-week 
intervention period. Therefore, it is difficult to interpret the effect of high-protein meals 
provided during dialysis on the QoL of HD patients.  
Based on responses for the End of Study questionnaire, patients generally had 
positive attitudes toward high-protein, renal-appropriate meals provided during dialysis in 
addition to showing difficulties with eating nutritiously or following a renal diet. 
Interestingly, however, providing meals had no effect of either making patients more or 
less interested in receiving meals compared with controls. Taste was rated as an 
important or very important factor in deciding what to eat by 88% of our patients, which 
is similar to the general US population (84%). However, a greater percentage of our 
patients rated convenience and nutrition as important or very important (76%, and 78%, 
respectively) compared with the general US population (52% and 64%, respectively) 
when determining what to eat, and a slightly greater percentage of our patients rated price 
as important or very important (74%) compared with only 6% of the general US 
population [104]. This indicates that, like the general population, HD patients find taste 
the most important factor in deciding what to eat. But, our results suggest that HD 
patients are more concerned about nutrition and convenience than the general population. 




along with perhaps a greater need for meal convenience to fit with dialysis schedules 
perhaps compounded by fatigue and lack of energy to prepare complex meals. 
  There are a number of limitations to this study due to its study design. First, the 
duration of study was likely not long enough to examine the effect of high-protein meals 
during dialysis on nutritional status indicators, especially serum albumin. If the study 
period was longer, we may have detected significant changes over time as other studies 
did. Also, it is possible that high-protein meals would only have a detectable effect on 
serum albumin in patients with sufficiently low baseline levels. Additionally, a future 
study should include measurement of markers of inflammation, such as CRP, to better 
assess baseline inflammation and effects of high-protein meals on inflammation, which 
may confound nutritional status outcomes. Second, this study was designed similar to a 
community research setting rather than a controlled research environment. Thus, patients 
were allowed to refuse any portion of their meal and were not encouraged to eat anything 
beyond their will. Additionally, some patients received prescribed nutritional 
supplements, or brought small snacks of their own, and this was not restricted as part of 
the study. Thus, our study represents much more of an “effectiveness” study than an 
“efficacy” study. A more controlled intervention would be necessary to better assess 
efficacy of providing high-protein meals. Third, baseline characteristics of patients were 
not evenly distributed due to non-randomized study design that was dictated by practical 
aspects of the layout of dialysis centers. This uneven distribution did result in significant 
differences between groups in some baseline attributes such as lower BP measures in the 
intervention group. However, the intervention group still did not experience an increase 




susceptible to these outcomes. This further supports our primary finding that high-protein 
meals during dialysis do not increase the frequency of SH events. Fourth, we did not 
adjust for the number of tests (aside from the Tukey adjustments for post-hoc 
comparisons within each ANOVA), which increases the risk of type I error. However, 
due to exploratory characters of pilot study, we retained the significance level at alpha 
0.05. Lastly, small sample size was another limitation as it was not powered to detect the 
effect of high-protein meals during dialysis on nutritional outcomes.  
 Despite these limitations, there are strengths of this study. First, well-designed 
meals that meet recommendations set by the KDOQI guidelines were used for this study. 
This suggests this approach is easy to follow and safe for HD patients. Second, we 
studied the effect of high-protein meals during dialysis on pre-albumin, which has not 
been included in previous studies. Despite the unfortunate fact that our baseline samples 
for pre-albumin were discarded, our findings regarding pre-albumin were novel showing 
values remained stable between mid-study and end of study in the intervention group, but 
dropped over the same time frame in the control group (though this interaction effect fell 
short of statistical significance). Lastly, we collected data from two months prior to the 
initiation of the study for the direct assessment of changes induced by meals provided 
during HD using each patient as their own comparator.  
 In summary, HD patients are in highly catabolic stage due to their disease state 
and dialysis treatment. In order to attenuate the rate and consequences of 
hypercatabolism, providing adequate nutrients in forms of oral nutritional supplements 
and/or meals during dialysis may be a solution. There are conflicting studies regarding 




suggesting that providing meals could be a safe approach to meeting the nutritional needs 
of these patients. However, our pilot study did not show improvements in nutritional 
status indicators, electrolyte balance, and dialysis compliance with meals. Our findings 
suggest the provision of meals that meet nutrient recommendations set by the KDOQI 
guidelines is safe and tolerable in HD patients.  
 
4.1 Future Directions 
Future multi-site studies with larger sample sizes and longer intervention periods 
are necessary to confirm the findings of our pilot study and to determine the effects of 
high-protein meals during dialysis on nutritional status and other QoL outcomes, and 
ultimately morbidity and mortality. When determining the duration of the intervention, a 
half-life of albumin should be considered in order to detect possible changes induced by 
meals provided during dialysis. Along with serum albumin, pre-albumin also should be 
included in data collection and analyses due to its reliability as a nutritional status 
indicator and ability to predict mortality in HD patients. If measured more frequently, 
pre-albumin may be able to detect acute changes in nutritional status in patients.  
Because albumin and pre-albumin are negative acute phase reactants, including 
inflammation markers (CRP and IL-6) may be beneficial as such data may be able to 
explain if changes in albumin and pre-albumin are induced by changes in protein intake 
or the presence or absence of inflammation. Also, grouping patients based on their 
baseline serum albumin level may be helpful in determining if patients with higher serum 




When designing meals, patients’ baseline daily protein consumption should be 
considered as some patients need more protein during dialysis than others. It also would 
be beneficial to determine the effects of providing high-protein meals during dialysis on 
overall renal diet adherence, including determining effects on the frequency of fast food 
consumption. This information would be helpful in providing a plausible mechanism 
(better renal diet adherence including controlled sodium intake) to explain our finding 
that meals during dialysis decreased IDWG in HD patients. 
 
4.2 Conclusion 
Our study shows that high-protein, renal-appropriate meals provided during 
dialysis do not increase the frequency of SH events in HD patients. This result further 
supports studies that encourage the provision of food or oral nutritional supplements 
during dialysis. Even though meals during dialysis did not improve nutritional status, 
electrolyte balance, and QoL of HD patients, this gives us another opportunity to 
reconsider pros and cons of high-protein meals provided during dialysis. Despite several 
limitations, this study sets a foundation for a further prospective intervention study with 
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Appendix A Study Design 
 





Appendix B “Appetite, Mood, and Symptoms” Questionnaire 
 
 


































Appendix C “End of Study” Questionnaire 
 
 
• Responses were recorded on a 5-point Likert scale. 
o 1 = very difficult; 5 = very easy 
o 1 = not at all interested; 5 = very interested. 




Appendix D Individual Serum Albumin Data 
 
Figure D.1. Changes in Serum Albumin in Each Patient in the Intervention Group 
from Pre-Study to During Study  
 
 
Figure D.2. Changes in Serum Albumin in Each Patient in the Intervention Group 



















































Appendix D continued 
Figure D.3. Changes in Serum Albumin in Each Patient in the Control Group from 
Pre-Study to During Study 
 
 
Figure D.4. Changes in Serum Albumin in Each Patient in the Control Group from 




























































Appendix D continued 
 
Figure D.5. Changes in Pre-albumin in Each Patient in the Intervention Group from 
During Study to End of Study 
  
 
Figure D.6. Changes in Pre-albumin in Each Patient in the Control Group from 



















































Appendix E Individual Interdialytic Weight Gain Data 
 
Table E.4.1. Interdialytic Weight Gain in the Intervention Group 
Subject Pre-Study During Study 
101 1.85 ± 0.91 1.68 ± 0.82 
102 1.50 ± 1.39 0.56 ± 0.42 
103 2.30 ± 2.08 1.77 ± 1.03 
104 3.77 ± 1.39 3.01 ± 0.63 
105 2.28 ± 1.64 1.81 ± 1.14 
106 3.53 ± 0.95 2.84 ± 0.83 
107 3.81 ± 2.45 1.40 ± 1.91 
108 1.50 ± 2.17 1.03 ± 0.79 
110 2.75 ± 0.62 2.25 ± 0.74 
Means 2.59 ± 1.51 1.82 ± 0.92 
Data are represented as mean ± SD. 
 
Table E.4.2. Interdialytic Weight Gain in the Control Group 
Subject Pre-Study During Study 
231 0.23 ± 0.76 0.26 ± 0.82 
232 2.10 ± 0.92 2.52 ± 1.06 
233 2.41 ± 1.58 2.20 ± 2.62 
234 1.80 ± 1.18 2.07 ± 1.10 
235 3.16 ± 1.50 3.70 ± 1.98 
236 2.27 ± 1.03 1.98 ± 0.97 
237 2.78 ± 0.94 2.73 ± 1.01 
238 2.35 ± 0.86 2.36 ± 0.79 
239 3.58 ± 1.56 2.47 ± 4.42 
Means 2.30 ± 1.15 2.26 ± 1.64 
Data are represented as mean ± SD. 
